EARS Auris Medical Holding Ltd.

-0.01  -2%
Previous Close 0.32
Open 0.31
Price To Book 3.13
Market Cap 11728705
Shares 37,495,859
Volume 455,441
Short Ratio
Av. Daily Volume 1,161,148

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Open label safety trial data released April 24, 2017 and May 9, 2017.
Keyzilen (AM-101) - AMPACT open-label
Acute inner ear tinnitus
Phase 3 HEALOS trial did not meet primary endpoint - November 28, 2017.
Acute inner ear hearing loss
Phase 3 data released March 13, 2018 - primary endpoint not met.
Keyzilen (AM-101) - TACTT3
Acute inner ear tinnitus
Phase 3 ASSENT trial terminated - November 28, 2017.
Acute inner ear hearing loss
Phase 2 trial (REACH) enrollment pending funding.
Surgery-induced hearing loss
Phase 3 trial did not meet primary endpoints
AM-101 (Keyzilen) - TACTT2
Acute inner ear tinnitus
Phase 2 trial in planning process - noted March 14, 2019.
Phase 1b top-line data due 3Q 2019.
Healthy volunteers

Latest News

  1. Buyer's Remorse? OTC Stock Zoom Technologies Zooms Higher Amid Potential Buyer Confusion
  2. Auris Medical Receives Positive Nasdaq Listing Determination
  3. Auris Medical Announces Randomization of First Dose Cohort in AM-201 Phase 1b Proof-of-Concept Study
  4. Auris Medical Announces 20-F Filing
  5. These Four Healthcare Stocks Could Test March Highs
  6. Auris: 4Q Earnings Snapshot
  7. Auris Medical Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results
  8. Auris Medical Announces Publication of AM-111 Phase 3 Results in Peer-Reviewed Scientific Journal
  9. Auris Medical to Report Fourth Quarter and Full Year 2018 Financial Results and Provide Business Update on Thursday, March 14, 2019
  10. Auris Medical Announces Receipt of Nasdaq Notice
  11. Auris Medical Announces Full Repayment of Hercules Loan Facility
  12. Auris Medical to Redomicile Holding Company from Switzerland to Bermuda
  13. 4 Healthcare Stocks Making Moves On Wednesday (1/23/19)
  14. Auris Medical Announces Publication of New Data Highlighting the Role of Betahistine in Promoting the Restoration of Forgotten Memories in Mice and Healthy Volunteers
  15. Auris Medical Provides Update on Intranasal Betahistine Programs
  16. New Healthcare Trends Pushing Stocks Higher On Thursday
  17. Auris Medical Announces Acquisition of Orphan Drug Designation and Secures Rights to In-License Additional Patents Related to Betahistine
  18. Biotech and Cannabis Stocks to Watch
  19. Detailed Research: Economic Perspectives on Wingstop, Marlin Business Services, Aware, Zynerba Pharmaceuticals, Auris Medical Holding AG, and Gulf Island Fabrication — What Drives Growth in Today's Competitive Landscape